Natus Medical Inc

Natus Medical, Inc. provides medical device solutions focuses on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Its products are used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, sleep disorders, neuromuscular diseases and balance and mobility disorders. The company was founded by Maurizio Liverani, John Robert Camber Porter, William New, Jr., Brian Prinn and William W. Moore on May 26, 1987 and is headquartered in Middleton, WI.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Natus Medical, Inc. engages in providing healthcare solutions. It also focuses on the diagnosis and treatment of central nervous and sensory system disorders. The company was founded by Maurizio Liverani, John Robert Camber Porter, William Jr. New, Brian Prinn and William W. Moore on May 26, 1987 and is headquartered in Middleton, WI.

Natus Medical (NTUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Natus Medical (NTUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

PLEASANTON, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced preliminary 2021 fourth quarter and full year revenue.

Natus Announces Preliminary 2021 Fourth Quarter and Full Year Revenue

PLEASANTON, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced that Thomas J. Sullivan, President and Chief Executive Officer, and Drew Davies, Executive Vice President and Chief Financial Officer, will be presenting at the 24th Annual Needham Virtual Growth Conference from 2:00 PM to 2:40 PM ET on Friday, January 14th.

Natus to Participate in the 24th Annual Needham Virtual Growth Conference

PLEASANTON, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 fourth quarter financial results after the close of the market on Thursday, February 24th. Natus management will host a conference call on Friday, February 25th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions.

Natus Medical to Hold 2021 Fourth Quarter Financial Results Conference Call on February 25th

Thomas J. Sullivan Appointed President & Chief Executive Officer

Natus Medical Announces Executive Transition

Natus Medical Incorporated's (NTUS) CEO Jonathan Kennedy on Q3 2021 Results - Earnings Call Transcript

Natus Medical (NTUS) delivered earnings and revenue surprises of -6.67% and -2.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Natus Medical (NTUS) Misses Q3 Earnings and Revenue Estimates

PLEASANTON, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced financial results for the three and nine months ended September 30, 2021.

Natus Medical Announces Third Quarter 2021 Financial Results

PLEASANTON, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company's Board of Directors established an Environmental, Social, and Governance (ESG) committee and transitioned the role of the Quality & Compliance Committee to the Innovation & Quality committee on September 30th, 2021.

Natus Medical Board of Directors Strengthens Governance and Focuses on Growth

PLEASANTON, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 third quarter financial results after the close of the market on Thursday, November 4th. Natus management will host a conference call on Friday, November 5th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions.

Natus Medical to Hold 2021 Third Quarter Financial Results Conference Call on November 5th

Paves the Way for Purchase of Natus Medical Equipment Through United States Government Healthcare System Electronic Catalog Paves the Way for Purchase of Natus Medical Equipment Through United States Government Healthcare System Electronic Catalog

Natus Medical Awarded Key New Government Contract

PLEASANTON, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointments of Bryant M. Moore, Ph.D. and Eric J. Guerin to the Company's Board of Directors. With these appointments, the Natus Board will be expanded to eight members.

Bryant M. Moore, Ph.D. and Eric J.

Natus Medical's (NTUS) CEO Jonathan Kennedy on Q2 2021 Results - Earnings Call Transcript

Natus Medical (NTUS) delivered earnings and revenue surprises of 0.00% and 0.76%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Natus Medical (NTUS) Q2 Earnings Match Estimates

PLEASANTON, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced financial results for the three and six months ended June 30, 2021.

Natus Medical Announces Second Quarter 2021 Financial Results

Launch to US Market of XactTrodes for Epilepsy Surgical Monitoring Launch to US Market of XactTrodes for Epilepsy Surgical Monitoring

First Case Performed Using Natus XactTrode™ Subdural Electrodes

PLEASANTON, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 second quarter financial results after the close of the market on Thursday, August 5th. Natus management will host a conference call on Friday, August 6th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions.

Natus Medical to Hold 2021 Second Quarter Financial Results Conference Call on August 6th

PLEASANTON, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced Dr. Barbara Paul, the Chairperson of the Board of Directors will retire from the Board effective June 30, 2021. The Board has elected independent director Joshua Levine who has served on the Natus board since 2018 as the new Chairperson.

Natus Chairperson Dr. Barbara Paul Retires; Board Elects Current Board Member Joshua Levine as Chairperson

Natus Medical Incorporated (NTUS) CEO Jonathan Kennedy on Q1 2021 Results - Earnings Call Transcript

Natus Medical (NTUS) delivered earnings and revenue surprises of 0.00% and 3.17%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Natus Medical (NTUS) Q1 Earnings Match Estimates

Natus Medical (NTUS) Earnings Expected to Grow: Should You Buy?

Natus Medical (NTUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Natus Medical (NTUS) Surges 6.6%: Is This an Indication of Further Gains?

ENDRA Life Sciences

Owens & Minor

Penumbra

Apollo Medical Hlds

Here are a few MedTech stocks, Natus Medical (NTUS), Owens & Minor (OMI), ENDRA Life Sciences (NDRA), Penumbra (PEN), Apollo Medical (AMEH), which might be prudent investment choices now.

5 MedTech Outperformers With Nearly 40% or More Gain in 2021

PLEASANTON, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced that Jonathan Kennedy, President and Chief Executive Officer and Drew Davies, Executive Vice President and Chief Financial Officer will be presenting from 3:00 p.m. to 3:40 p.m. Eastern Time and hosting one-on-one meetings during the day with institutional investors at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15th.

Natus to Participate in the 20th Annual Needham Virtual Healthcare Conference

PLEASANTON, Calif., April 01, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 first quarter financial results after the close of the market on Thursday, May 6th. Natus management will host a conference call the same day beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss those results and to answer questions.

News for Natus Medical Inc Stock (NTUS)